Anthropic Commits $11.6 Billion to Akamai Compute Deal, Expandable to About $20 Billion
SentiSense · Published · Updated
Akamai announced a seven-year, $11.6 billion contractual commitment from Anthropic for distributed AI compute, with room to expand by up to $9 billion more for a potential total of about $20 billion. Akamai also granted Anthropic a warrant for up to about 5% of its stock, and its shares jumped more than 20% after hours. The same day, Anthropic widened its medical AI reach with OpenEvidence and touted an agent-driven biology finding.
AKAM announced on September 24 that Anthropic has signed a multi-year agreement worth $11.6 billion in contractual commitments over seven years, with a potential expansion of up to an additional $9 billion that would take the total to about $20 billion . Anthropic is the customer here: Akamai will supply distributed AI infrastructure and software, described as a continuum of compute from core to edge across its network, to support Anthropic's workloads. Akamai shares jumped more than 20% in after-hours trading on the news.
The deal carries unusual terms for a cloud contract. Akamai expects roughly $5.5 billion of capital spending tied to the commitment, including about $1.7 billion in 2026, and it issued Anthropic a warrant for up to about 5% of Akamai's common stock at an exercise price of $111.33 per share. Roughly 2% vests with the base commitment and the remaining 3% only if the relationship expands by the additional $9 billion, which aligns Anthropic with Akamai's equity upside as its spending grows.
The compute deal landed alongside two product-side moves. Anthropic is supplying model capacity for a version of OpenEvidence's clinical decision-support tool offered free to physicians in about 100 low- and middle-income countries, with no financial terms disclosed . Anthropic also said about 950 Claude-powered agents, running for 21 hours, scanned a DNA-sequence database and narrowed more than 200,000 genes to 20 candidates, surfacing a possible CRISPR-like system it calls ART that it describes as preliminary. Separately, the Wall Street Journal reported that Anthropic staff, including Frontier Red Team head Logan Graham, personally invested in Pilgrim, a biothreat-detection startup that raised a $25 million seed round at a $150 million valuation; this was not a corporate Anthropic investment.
For Akamai, the questions are execution and concentration: a single customer now anchors a large capex program, so watch how quickly the 2026 spending converts into recognized revenue and whether the $9 billion expansion is triggered. For the AI infrastructure trade, the deal is another sign that frontier labs are spreading compute purchases beyond the hyperscalers to edge and CDN operators.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis